Transcatheter Aortic Valve Replacement: 2015 in Review

Harjai, Kishore J.; Grines, Cindy L.; Leon, Martin B.

doi:10.1111/joic.12274

Cited by 7 publications

(4 citation statements)

References 114 publications

(194 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Last year, we published a year‐in‐review article on TAVR . This article summarizes the major publications on TAVR from December 2015 through December 2016.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter aortic valve replacement: The year in review 2016

Harjai

Grines

Paradis

et al. 2017

J Interven Cardiology

Self Cite

View full text Add to dashboard Cite

Transcatheter aortic valve replacement (TAVR) continued to make major strides in 2016, simultaneously expanding its application to lower risk patients as well as more technically challenging subsets of patients with aortic stenosis (AS). The two major accomplishments this year were the establishment of TAVR as the preferred treatment strategy over surgical aortic valve replacement (SAVR) in intermediate risk patients, and initial signals that TAVR and SAVR may be clinically equivalent in low-risk populations. Meanwhile, there is continued expansion of TAVR to challenging clinical subsets (bicuspid aortic valve [BAV], patients with concomitant advanced coronary artery disease [CAD], and failed surgical bioprostheses), and encouraging initial experiences with newer transcatheter heart valve systems. This paper summarizes the major research studies published on TAVR in 2016.

show abstract

“…Last year, we published a year‐in‐review article on TAVR . This article summarizes the major publications on TAVR from December 2015 through December 2016.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter aortic valve replacement: The year in review 2016

Harjai

Grines

Paradis

et al. 2017

J Interven Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Those variables were selected based on clinical significance referred to previous studies. 13,14 The results of the multivariable Cox regression analysis were expressed as hazard ratios (HR) for the comparison of risk with 95% confidence interval (CI). The logistic multivariable analysis was used to identify predictors of late TR progression.…”

Section: Discussionmentioning

confidence: 99%

Late Progression of Tricuspid Regurgitation After Transcatheter Aortic Valve Replacement

Muraishi¹,

Tabata

Shibayama³

et al. 2022

Journal of the Society for Cardiovascular Angiography & Int

View full text Add to dashboard Cite

“…The first human transcatheter aortic valve implantation (TAVI) was reported in a patient with severe aortic stenosis (AS) presenting with cardiogenic shock in 2002. 1 During recent years great progress was achieved in TAVI for native degenerated aortic valves. 2 Different transcatheter heart valves were designed 3 and long term follow up are available.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)

Zeinali

Abbasi

et al. 2017

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: After early successful experience with transcatheter aortic valve replacement (TAVR), concept of transcatheter implantation of a new valve within a failing bioprosthetic valve emerged. Valve-in-valve (ViV) implantation seems to be a simpler option for high risk surgical patients. Methods: We performed five ViV procedures in different valve positions. We included patients with failing bioprosthetic valves with high surgical risk due to concomitant comorbidities. We performed 2 transapical ViV procedures for failing mitral bioprosthetic valves, 1 transfemoral procedure for failing pulmonary valve and 2 transfemoral ViV implantation for failing tricuspid bioprosthetic valves. Results: The procedures were successfully completed in all 5 cases with initial excellent fluoroscopic and echocardiographic verification. There was no valve embolization or paravalvular leakage in any of the cases. Transcatheter valve function was appropriate with echocardiography. Post procedural clinical adverse events like pleural effusion and transient ischemic attack were managed successfully. In midterm follow up all cases remained in appropriate functional class except from the transcatheter pulmonary valve which became moderately stenotic and regurgitant. Conclusion: As the first Iranian all-comers case series with midterm follow up for ViV implantation, we had no mortality. Interestingly none of our patients had neurologic sequelae after the procedure. Midterm follow up for our patients was acceptable with good functional class and appropriate echocardiographic findings. Due to high surgical risk of the redo procedure after failing of a bioprosthetic valve especially in elderly patients with comorbidities, ViV implantation would be a good alternative to surgery for this high risk group.

show abstract

Transcatheter Aortic Valve Replacement: 2015 in Review

Cited by 7 publications

References 114 publications

Transcatheter aortic valve replacement: The year in review 2016

Transcatheter aortic valve replacement: The year in review 2016

Late Progression of Tricuspid Regurgitation After Transcatheter Aortic Valve Replacement

Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)

Contact Info

Product

Resources

About